期刊文献+

心理干预在厄洛替尼致皮疹患者中的应用

Psychological intervention during erlotinib induced rash patients application
暂未订购
导出
摘要 目的:针对肺癌口服厄洛替尼致皮疹患者的心理负面情绪,采取相应的心理干预措施,以提高治疗效果改善患者的生活质量及心理状态。方法:作者对2010年10月~2012年3月我科所收治38例肺癌口服厄洛替尼致皮疹患者进行心理分析,应用健康教育、沟通、创建支持系统等干预措施。结果:通过心理干预,均能消除或减轻患者的心理负面情绪。结论:对肺癌口服厄洛替尼致皮疹患者心理状态进行分析,给予适宜的心理干预及健康教育措施,对提高患者用药依从性及生活质量均有积极意义。 Objective For lung cancer oral erlotinib cause rash patients psychological negative emotions,and take the corresponding psychological intervention measures,in order to improve treatment effect to improve the patient's quality of life and psychological state. Methods The authors in October 2010 to March 2012 I branch of 38 cases of lung cancer were oral erlotinib cause rash patients psychological analysis,the application of health education,communication,create support system and intervention measures. Results Through the psychological intervention,all can eliminate or relieve the patient's psychological negative emotions. Conclusion The lung cancer oral erlotinib cause rash patients psychological state were analyzed,and give appropriate psychological intervention and health education measures,to improve patients medication compliance and quality of life have the positive significance.
作者 吴洁
出处 《中国美容医学》 CAS 2012年第10X期444-445,共2页 Chinese Journal of Aesthetic Medicine
关键词 厄洛替尼 皮疹 心理负面情绪 心理干预 erlotinib Rash Psychological negative emotions Psychological intervention
  • 相关文献

参考文献1

二级参考文献14

  • 1[1]Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase Ⅲ trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [C]. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology;June 5-8, 2004; New Orleans, Louisiana. Abstract 7010.
  • 2[2]Herbst RS, Prager D, Hermann R, et al. TRIBUTE:a phase Ⅲ trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [C]. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology;June 5-8,2004; New Orleans, Louisiana. Abstract 7011.
  • 3[3]Shepherd FA, PereiraJ, CiuleanuTE, etal. Arandomized placebo-controlled trial or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy [C]. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, Louisiana.Abstract 7022.
  • 4[4]Giaccone G, Johnson DH, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839( ‘Iressa' ) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non small-cell lung cancer (INTACT 1) [abstract no. 4] [J]. Ann Oncol, 2002, 13:2.
  • 5[5]Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa")in combination with paclitaxel and carboplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC): resukse Ⅲ clinical trial (INTACT 2) [abstract no.468] [J]. Ann Oncol, 2002, 13:127.
  • 6[6]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003, 22(12): 2237-2246.
  • 7[7]Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine, in symptomatic patients with non-small cell lung cancer [J ]. JAMA,2003, 290(16) :2149-2158.
  • 8[8]Coiffier B. Related ArRituximab in combination with CHOP improves survival in elderly patients with aggressive non Hodgkin's lymphoma [J]. Semin Oncol, 2002, 29(2 Suppl 6):18-22.
  • 9[9]Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001,344:783-792.
  • 10[10]Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents [J]. Drugs, 2000, 60(suppl 1):25-32.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部